{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:38:05Z","timestamp":1779291485168,"version":"3.51.4"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) has transitioned from an underrecognized and poorly characterized condition to a recognized, increasingly prevalent form of heart failure in the adult population, accounting for approximately half of all heart failure cases. Improved diagnostic capabilities and the growing burden of risk factors, including aging, hypertension, diabetes, and obesity, drive this rise. In contrast, pediatric HFpEF remains largely under-characterized, arising in a heterogeneous context that includes congenital heart disease and restrictive cardiomyopathies. The true incidence and prevalence of pediatric HFpEF remain difficult to establish due to challenges such as the absence of standardized diagnostic criteria, limited sensitivity of conventional diastolic function parameters, a lack of age-specific reference ranges for imaging and biomarker thresholds, and nonspecific symptoms that complicate early detection. While recent pharmacological advances in adult HFpEF, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists, have demonstrated incremental benefits, there is a notable absence of evidence-based treatments for pediatric HFpEF. This review provides an up-to-date overview of pediatric HFpEF, highlighting key diagnostic challenges and therapeutic gaps, discussing recent advancements in diagnostics and emerging therapeutic strategies with potential relevance for pediatric care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This article addresses pediatric heart failure with preserved ejection fraction (HFpEF), a condition that is emerging in the pediatric population. While HFpEF is a well-established and prevalent condition in adults, its prevalence in children remains underrecognized and poorly understood.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This article highlights key challenges in diagnosing and managing pediatric HFpEF, including the absence of standardized diagnostic criteria, limited sensitivity of traditional diastolic function measures, and a lack of age-specific imaging biomarkers.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In this up-to-date review, we discuss those limitations, emphasizing the need for greater research into its pathophysiology and therapeutic strategies.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-026-05038-9","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:40:25Z","timestamp":1779284425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current concepts and challenges in pediatric diastolic dysfunction and heart failure with preserved ejection fraction"],"prefix":"10.1038","author":[{"given":"Luke D.","family":"Losordo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadir","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Belk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Booz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Monafo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"5038_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1071-9164(97)90019-1","volume":"3","author":"DL Brutsaert","year":"1997","unstructured":"Brutsaert, D. L. & Sys, S. U. Diastolic dysfunction in heart failure. J. Card. Fail. 3, 225\u2013242 (1997).","journal-title":"J. Card. Fail."},{"key":"5038_CR2","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/hc1202.105290","volume":"105","author":"MR Zile","year":"2002","unstructured":"Zile, M. R. & Brutsaert, D. L. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 105, 1503\u20131508 (2002).","journal-title":"Circulation"},{"key":"5038_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug, B. A. The pathophysiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 11, 507\u2013515 (2014).","journal-title":"Nat. Rev. Cardiol."},{"key":"5038_CR4","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson, M. M. et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology solution set oversight committee. J. Am. Coll. Cardiol. 81, 1835\u20131878 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5038_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.846408","volume":"10","author":"B Pan","year":"2022","unstructured":"Pan, B. et al. Pediatric diastolic heart failure: clinical features description of 421 cases. Front. Pediatr. 10, 846408 (2022).","journal-title":"Front. Pediatr."},{"key":"5038_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy, S. P., Ibrahim, N. E. & Januzzi, J. L. Jr Heart failure with reduced ejection fraction: a review. JAMA 324, 488\u2013504 (2020).","journal-title":"JAMA"},{"key":"5038_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","volume":"17","author":"BA Borlaug","year":"2020","unstructured":"Borlaug, B. A. Evaluation and management of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 17, 559\u2013573 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"5038_CR8","doi-asserted-by":"publisher","first-page":"101907","DOI":"10.1016\/j.jacadv.2025.101907","volume":"4","author":"G Norrish","year":"2025","unstructured":"Norrish, G. et al. Sex differences in children and adolescents with hypertrophic cardiomyopathy. JACC Adv. 4, 101907 (2025).","journal-title":"JACC Adv."},{"key":"5038_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/pdi3.50","volume":"1","author":"S Huang","year":"2023","unstructured":"Huang, S. et al. Pediatric heart failure classification based on left ventricular ejection fraction. Pediatr. Discov. 1, e50 (2023).","journal-title":"Pediatr. Discov."},{"key":"5038_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.yjmcc.2018.11.009","volume":"126","author":"KC Woulfe","year":"2019","unstructured":"Woulfe, K. C. & Bruns, D. R. From pediatrics to geriatrics: mechanisms of heart failure across the life-course. J. Mol. Cell Cardiol. 126, 70\u201376 (2019).","journal-title":"J. Mol. Cell Cardiol."},{"key":"5038_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3345\/cep.2023.00528","volume":"67","author":"A Agrawal","year":"2024","unstructured":"Agrawal, A., Janjua, D., Alsayed Ali Zeyada, A. A. & Taher Elsheikh, A. Heart failure in children and adolescents: an update on diagnostic approaches and management. Clin. Exp. Pediatr. 67, 178\u2013190 (2024).","journal-title":"Clin. Exp. Pediatr."},{"key":"5038_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00246-022-02960-7","volume":"44","author":"B Das","year":"2023","unstructured":"Das, B. et al. Heart failure with preserved ejection fraction in children. Pediatr. Cardiol. 44, 513\u2013529 (2023).","journal-title":"Pediatr. Cardiol."},{"key":"5038_CR13","doi-asserted-by":"publisher","first-page":"1137853","DOI":"10.3389\/fped.2023.1137853","volume":"11","author":"S Quennelle","year":"2023","unstructured":"Quennelle, S. & Bonnet, D. Pediatric heart failure with preserved ejection fraction, a review. Front. Pediatr. 11, 1137853 (2023).","journal-title":"Front. Pediatr."},{"key":"5038_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/PCC.0000000000002668","volume":"22","author":"S Ginsburg","year":"2021","unstructured":"Ginsburg, S. et al. Left ventricular diastolic dysfunction in pediatric sepsis: outcomes in a single-center retrospective cohort study. Pediatr. Crit. Care Med. 22, 275\u2013285 (2021).","journal-title":"Pediatr. Crit. Care Med."},{"key":"5038_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2021.03.066","volume":"235","author":"JN Abdul-Raheem","year":"2021","unstructured":"Abdul-Raheem, J. N. et al. Left ventricular diastolic dysfunction among youth with obesity and history of elevated blood pressure. J. Pediatr. 235, 130\u2013137 (2021).","journal-title":"J. Pediatr."},{"key":"5038_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133672","volume":"440","author":"VP Kassab","year":"2025","unstructured":"Kassab, V. P. et al. Evaluation of early diagnosis and progression to heart failure with preserved ejection fraction: a retrospective study in patients with arterial hypertension and left ventricular hypertrophy. Int. J. Cardiol. 440, 133672 (2025).","journal-title":"Int. J. Cardiol."},{"key":"5038_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009446","volume":"16","author":"KS Takvorian","year":"2023","unstructured":"Takvorian, K. S. et al. The association of protein biomarkers with incident heart failure with preserved and reduced ejection fraction. Circ. Heart Fail. 16, e009446 (2023).","journal-title":"Circ. Heart Fail."},{"key":"5038_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12471-016-0817-7","volume":"24","author":"WC Meijers","year":"2016","unstructured":"Meijers, W. C., van der Velde, A. R. & de Boer, R. A. Biomarkers in heart failure with preserved ejection fraction. Neth. Heart J. 24, 252\u2013258 (2016).","journal-title":"Neth. Heart J."},{"key":"5038_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10741-024-10442-6","volume":"30","author":"LA Ammar","year":"2025","unstructured":"Ammar, L. A. et al. Bnp and Nt-Probnp as prognostic biomarkers for the prediction of adverse outcomes in HFPEF patients: a systematic review and meta-analysis. Heart Fai.l Rev. 30, 45\u201354 (2025).","journal-title":"Heart Fai.l Rev."},{"key":"5038_CR20","doi-asserted-by":"crossref","unstructured":"Boichenko, V. et al. Circulating non-coding RNAs as indicators of fibrosis and heart failure severity. Cells 14, 553 (2025).","DOI":"10.3390\/cells14070553"},{"key":"5038_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12471-016-0812-z","volume":"24","author":"C Franssen","year":"2016","unstructured":"Franssen, C. & Gonzalez Miqueo, A. The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth. Heart J. 24, 259\u2013267 (2016).","journal-title":"Neth. Heart J."},{"key":"5038_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus, W. J. & Tschope, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62, 263\u2013271 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5038_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/FJC.0000000000001228","volume":"79","author":"MG McCandless","year":"2022","unstructured":"McCandless, M. G., Altara, R., Booz, G. W. & Kurdi, M. What role do mitochondria have in diastolic dysfunction? Implications for diabetic cardiomyopathy and heart failure with preserved ejection function. J. Cardiovasc Pharm. 79, 399\u2013406 (2022).","journal-title":"J. Cardiovasc Pharm."},{"key":"5038_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1161\/CIRCULATIONAHA.118.035711","volume":"138","author":"WJ Paulus","year":"2018","unstructured":"Paulus, W. J. H(2)Fpef score: at last, a properly validated diagnostic algorithm for heart failure with preserved ejection fraction. Circulation 138, 871\u2013873 (2018).","journal-title":"Circulation"},{"key":"5038_CR25","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske, B. et al. How to diagnose heart failure with preserved ejection fraction: the Hfa-Peff diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. Heart J. 40, 3297\u20133317 (2019).","journal-title":"Eur. Heart J."},{"key":"5038_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","volume":"7","author":"G Savarese","year":"2019","unstructured":"Savarese, G. et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail. 7, 306\u2013317 (2019).","journal-title":"JACC Heart Fail."},{"key":"5038_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/CIRCULATIONAHA.121.058592","volume":"146","author":"H Sorimachi","year":"2022","unstructured":"Sorimachi, H. et al. Longitudinal evolution of cardiac dysfunction in heart failure and preserved ejection fraction with normal natriuretic peptide levels. Circulation 146, 500\u2013502 (2022).","journal-title":"Circulation"},{"key":"5038_CR28","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","volume":"5","author":"SM Dunlay","year":"2012","unstructured":"Dunlay, S. M., Roger, V. L., Weston, S. A., Jiang, R. & Redfield, M. M. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ. Heart Fail. 5, 720\u2013726 (2012).","journal-title":"Circ. Heart Fail."},{"key":"5038_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ehjdh\/ztaa015","volume":"2","author":"JM Kwon","year":"2021","unstructured":"Kwon, J. M. et al. Artificial intelligence assessment for early detection of heart failure with preserved ejection fraction based on electrocardiographic features. Eur. Heart J. Digit Health 2, 106\u2013116 (2021).","journal-title":"Eur. Heart J. Digit Health"},{"key":"5038_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/ehjdh\/ztab081","volume":"2","author":"M Unterhuber","year":"2021","unstructured":"Unterhuber, M. et al. Deep learning detects heart failure with preserved ejection fraction using a baseline electrocardiogram. Eur. Heart J. Digit Health 2, 699\u2013703 (2021).","journal-title":"Eur. Heart J. Digit Health"},{"key":"5038_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58283-7","volume":"16","author":"AP Akerman","year":"2025","unstructured":"Akerman, A. P. et al. External validation of artificial intelligence for detection of heart failure with preserved ejection fraction. Nat. Commun. 16, 2915 (2025).","journal-title":"Nat. Commun."},{"key":"5038_CR32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s41591-021-01342-5","volume":"27","author":"R Arnaout","year":"2021","unstructured":"Arnaout, R. et al. An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease. Nat. Med. 27, 882\u2013891 (2021).","journal-title":"Nat. Med."},{"key":"5038_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132019","volume":"406","author":"Y Nogimori","year":"2024","unstructured":"Nogimori, Y. et al. Prediction of adverse cardiovascular events in children using artificial intelligence-based electrocardiogram. Int. J. Cardiol. 406, 132019 (2024).","journal-title":"Int. J. Cardiol."},{"key":"5038_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1161\/CIRCULATIONAHA.123.067750","volume":"149","author":"J Mayourian","year":"2024","unstructured":"Mayourian, J. et al. Pediatric ECG-based deep learning to predict left ventricular dysfunction and remodeling. Circulation 149, 917\u2013931 (2024).","journal-title":"Circulation"},{"key":"5038_CR35","doi-asserted-by":"crossref","unstructured":"Yi, J. E. & Cho, J. S. Artificial intelligence in Hfpef: diagnosis, prognosis, and management strategies. J. Cardiol. 87, 113\u2013120 (2025).","DOI":"10.1016\/j.jjcc.2025.08.018"},{"key":"5038_CR36","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1056\/NEJMoa1503840","volume":"374","author":"G Twig","year":"2016","unstructured":"Twig, G. et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. N. Engl. J. Med. 374, 2430\u20132440 (2016).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR37","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.jacc.2007.12.029","volume":"51","author":"HM Ippisch","year":"2008","unstructured":"Ippisch, H. M. et al. Reversibility of cardiac abnormalities in morbidly obese adolescents. J. Am. Coll. Cardiol. 51, 1342\u20131348 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5038_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1506699","volume":"374","author":"TH Inge","year":"2016","unstructured":"Inge, T. H. et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N. Engl. J. Med. 374, 113\u2013123 (2016).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR39","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s11695-021-05364-3","volume":"31","author":"W Elhag","year":"2021","unstructured":"Elhag, W. & El Ansari, W. Durability of cardiometabolic outcomes among adolescents after sleeve gastrectomy: first study with 9-year follow-up. Obes. Surg. 31, 2869\u20132877 (2021).","journal-title":"Obes. Surg."},{"key":"5038_CR40","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/oby.20495","volume":"21","author":"P Obert","year":"2013","unstructured":"Obert, P. et al. Impact of diet and exercise training-induced weight loss on myocardial mechanics in severely obese adolescents. Obesity 21, 2091\u20132098 (2013).","journal-title":"Obesity"},{"key":"5038_CR41","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jcmg.2018.05.023","volume":"11","author":"S Erbs","year":"2018","unstructured":"Erbs, S. et al. Impact of weight reduction during adolescence on parameters of cardiac geometry and function in obese children. JACC Cardiovasc. Imaging 11, 1915\u20131917 (2018).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"5038_CR42","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1056\/NEJMoa1010112","volume":"365","author":"M Juonala","year":"2011","unstructured":"Juonala, M. et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N. Engl. J. Med. 365, 1876\u20131885 (2011).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR43","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1161\/ATVBAHA.121.316265","volume":"41","author":"JM Kindblom","year":"2021","unstructured":"Kindblom, J. M. et al. Pubertal body mass index change is associated with adult coronary atherosclerosis and acute coronary events in men. Arterioscler. Thromb. Vasc. Biol. 41, 2318\u20132327 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"5038_CR44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10554-012-0174-6","volume":"29","author":"OJ Rider","year":"2013","unstructured":"Rider, O. J. et al. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int. J. Cardiovasc. Imaging 29, 1043\u20131050 (2013).","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"5038_CR45","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/S0002-9149(99)80338-5","volume":"76","author":"MA Alpert","year":"1995","unstructured":"Alpert, M. A. et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am. J. Cardiol. 76, 1194\u20131197 (1995).","journal-title":"Am. J. Cardiol."},{"key":"5038_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/01.CIR.71.3.481","volume":"71","author":"T Nakajima","year":"1985","unstructured":"Nakajima, T. et al. Noninvasive study of left ventricular performance in obese patients: influence of duration of obesity. Circulation 71, 481\u2013486 (1985).","journal-title":"Circulation"},{"key":"5038_CR47","doi-asserted-by":"publisher","first-page":"A05","DOI":"10.1161\/circ.129.suppl_1.05","volume":"129","author":"JP Reis","year":"2014","unstructured":"Reis, J. P. et al. Abstract 05: longer duration of obesity beginning in young adulthood is associated with greater left ventricular mass and worse left ventricular function in middle-age: the Cardia study. Circulation 129, A05\u2013A05 (2014).","journal-title":"Circulation"},{"key":"5038_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031722","volume":"13","author":"M Dalen","year":"2024","unstructured":"Dalen, M. et al. Long-term survival after single-ventricle palliation: a Swedish nationwide cohort study. J. Am. Heart Assoc. 13, e031722 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"5038_CR49","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1161\/CIRCULATIONAHA.118.036821","volume":"138","author":"ME Oster","year":"2018","unstructured":"Oster, M. E., Knight, J. H., Suthar, D., Amin, O. & Kochilas, L. K. Long-term outcomes in single-ventricle congenital heart disease. Circulation 138, 2718\u20132720 (2018).","journal-title":"Circulation"},{"key":"5038_CR50","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1016\/j.jacc.2017.03.582","volume":"69","author":"AM Atz","year":"2017","unstructured":"Atz, A. M. et al. Longitudinal outcomes of patients with single ventricle after the Fontan procedure. J. Am. Coll. Cardiol. 69, 2735\u20132744 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5038_CR51","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.healun.2014.06.002","volume":"33","author":"R Kirk","year":"2014","unstructured":"Kirk, R. et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: executive summary. [corrected]. J. Heart Lung Transpl. 33, 888\u2013909 (2014).","journal-title":"J. Heart Lung Transpl."},{"key":"5038_CR52","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1161\/CIR.0000000000001245","volume":"150","author":"S Amdani","year":"2024","unstructured":"Amdani, S. et al. Evaluation and management of chronic heart failure in children and adolescents with congenital heart disease: a scientific statement from the American Heart Association. Circulation 150, e33\u2013e50 (2024).","journal-title":"Circulation"},{"key":"5038_CR53","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.healun.2025.06.003","volume":"44","author":"C Irving","year":"2025","unstructured":"Irving, C. et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure (update from 2014). J. Heart Lung Transpl. 44, e21\u2013e71 (2025).","journal-title":"J. Heart Lung Transpl."},{"key":"5038_CR54","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 Aha\/Acc\/Hfsa Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895\u2013e1032 (2022).","journal-title":"Circulation"},{"key":"5038_CR55","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2020.06.022","volume":"76","author":"C Faselis","year":"2020","unstructured":"Faselis, C. et al. Loop diuretic prescription and 30-day outcomes in older patients with heart failure. J. Am. Coll. Cardiol. 76, 669\u2013679 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5038_CR56","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cardfail.2019.03.019","volume":"25","author":"JF Price","year":"2019","unstructured":"Price, J. F. et al. Diuretic responsiveness and its prognostic significance in children with heart failure. J. Card. Fail. 25, 941\u2013947 (2019).","journal-title":"J. Card. Fail."},{"key":"5038_CR57","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund, P. S. et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 404, 1119\u20131131 (2024).","journal-title":"Lancet"},{"key":"5038_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TopCat) trial. Circulation 131, 34\u201342 (2015).","journal-title":"Circulation"},{"key":"5038_CR59","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann, F. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-Dhf randomized controlled trial. JAMA 309, 781\u2013791 (2013).","journal-title":"JAMA"},{"key":"5038_CR60","doi-asserted-by":"publisher","first-page":"e290224227534","DOI":"10.2174\/011573403X281390240219063817","volume":"20","author":"EM Al-Hashedi","year":"2024","unstructured":"Al-Hashedi, E. M. & Abdu, F. A. Aldosterone effect on cardiac structure and function. Curr. Cardiol. Rev. 20, e290224227534 (2024).","journal-title":"Curr. Cardiol. Rev."},{"key":"5038_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/eurheartj\/ehr292","volume":"33","author":"F Edelmann","year":"2012","unstructured":"Edelmann, F. et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur. Heart J. 33, 203\u2013212 (2012).","journal-title":"Eur. Heart J."},{"key":"5038_CR62","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026071","volume":"11","author":"AN Smith","year":"2022","unstructured":"Smith, A. N. et al. Genomic, proteomic, and metabolic comparisons of small animal models of heart failure with preserved ejection fraction: a tale of mice, rats, and cats. J. Am. Heart Assoc. 11, e026071 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"5038_CR63","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027164","volume":"11","author":"B Hegyi","year":"2022","unstructured":"Hegyi, B. et al. Diabetes and excess aldosterone promote heart failure with preserved ejection fraction. J. Am. Heart Assoc. 11, e027164 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"5038_CR64","doi-asserted-by":"crossref","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 391, 1475\u20131485 (2024).","DOI":"10.1056\/NEJMe2410904"},{"key":"5038_CR65","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1253\/circj.CJ-12-1271","volume":"77","author":"S Masutani","year":"2013","unstructured":"Masutani, S. et al. Heart failure with preserved ejection fraction in children: hormonal imbalance between aldosterone and brain natriuretic peptide. Circ. J. 77, 2375\u20132382 (2013).","journal-title":"Circ. J."},{"key":"5038_CR66","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf, S. et al. Effects of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the charm-preserved trial. Lancet 362, 777\u2013781 (2003).","journal-title":"Lancet"},{"key":"5038_CR67","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie, B. M. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359, 2456\u20132467 (2008).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR68","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620 (2019).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR69","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","volume":"150","author":"R Shaddy","year":"2024","unstructured":"Shaddy, R. et al. Sacubitril\/valsartan in pediatric heart failure (panorama-Hf): a randomized, multicenter, double-blind trial. Circulation 150, 1756\u20131766 (2024).","journal-title":"Circulation"},{"key":"5038_CR70","doi-asserted-by":"crossref","unstructured":"Konduri, A. et al. Single-center experience with sacubitril\/valsartan in patients with congenital heart disease. Pediatr. Cardiol. 47, 1581\u20131590 (2025).","DOI":"10.1007\/s00246-025-03938-x"},{"key":"5038_CR71","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR72","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR73","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40272-024-00623-z","volume":"26","author":"SAG Lava","year":"2024","unstructured":"Lava, S. A. G. et al. Dapagliflozin and empagliflozin in paediatric indications: a systematic review. Paediatr. Drugs 26, 229\u2013243 (2024).","journal-title":"Paediatr. Drugs"},{"key":"5038_CR74","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","volume":"11","author":"LM Laffel","year":"2023","unstructured":"Laffel, L. M. et al. Efficacy and safety of the Sglt2 inhibitor empagliflozin versus placebo and the Dpp-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (Dinamo): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diab. Endocrinol. 11, 169\u2013181 (2023).","journal-title":"Lancet Diab. Endocrinol."},{"key":"5038_CR75","doi-asserted-by":"publisher","first-page":"EVIDoa2300210","DOI":"10.1056\/EVIDoa2300210","volume":"2","author":"N Shehadeh","year":"2023","unstructured":"Shehadeh, N. et al. Dapagliflozin or saxagliptin in pediatric type 2 diabetes. NEJM Evid. 2, EVIDoa2300210 (2023).","journal-title":"NEJM Evid."},{"key":"5038_CR76","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","volume":"10","author":"WV Tamborlane","year":"2022","unstructured":"Tamborlane, W. V. et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diab. Endocrinol. 10, 341\u2013350 (2022).","journal-title":"Lancet Diab. Endocrinol."},{"key":"5038_CR77","doi-asserted-by":"crossref","unstructured":"Newland, D. M. et al. Dapagliflozin use in children with advanced heart failure undergoing heart transplantation: a matched case-control study. Pediatr. Cardiol. 46, 1879\u20131884 (2024).","DOI":"10.1007\/s00246-024-03604-8"},{"key":"5038_CR78","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","volume":"44","author":"DM Newland","year":"2023","unstructured":"Newland, D. M. et al. Early clinical experience with dapagliflozin in children with heart failure. Pediatr. Cardiol. 44, 146\u2013152 (2023).","journal-title":"Pediatr. Cardiol."},{"key":"5038_CR79","doi-asserted-by":"publisher","first-page":"133384","DOI":"10.1016\/j.ijcard.2025.133384","volume":"435","author":"SS Kumar","year":"2025","unstructured":"Kumar, S. S., Gopalakrishnan, A., Krishnamoorthy, K. M., Naik, S. & Sivadasanpillai, H. The efficacy and safety of dapagliflozin in pediatric heart failure. Int J. Cardiol. 435, 133384 (2025).","journal-title":"Int J. Cardiol."},{"key":"5038_CR80","doi-asserted-by":"crossref","unstructured":"Butts, R. et al. Use of SGLT2 inhibitors in pediatric heart failure: a multi-center study. Pediatr. Cardiol. (2025). Online ahead of print.","DOI":"10.1007\/s00246-025-04025-x"},{"key":"5038_CR81","doi-asserted-by":"publisher","first-page":"419","DOI":"10.32604\/chd.2024.056608","volume":"19","author":"V Marshall","year":"2024","unstructured":"Marshall, V., William, H. & Wright, L. K. Sodium-glucose cotransporter 2 inhibitors in adult and pediatric congenital heart disease: review of emerging data and future directions. Congenit. Heart Dis. 19, 419\u2013433 (2024).","journal-title":"Congenit. Heart Dis."},{"key":"5038_CR82","doi-asserted-by":"publisher","first-page":"S479","DOI":"10.1016\/j.healun.2023.02.1326","volume":"42","author":"R Butts","year":"2023","unstructured":"Butts, R., Nandi, D., Hong, B., Lorts, A. & Spinner, J. (1115) Sglt2 inhibitor use in pediatric heart failure.  J. Heart Lung Transplant. 42, S479 (2023).","journal-title":"J. Heart Lung Transplant."},{"key":"5038_CR83","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00392-023-02362-6","volume":"113","author":"A Villaschi","year":"2024","unstructured":"Villaschi, A. et al. Glp-1-Ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. Clin. Res. Cardiol. 113, 898\u2013909 (2024).","journal-title":"Clin. Res. Cardiol."},{"key":"5038_CR84","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR85","doi-asserted-by":"publisher","first-page":"e0201836","DOI":"10.1371\/journal.pone.0201836","volume":"13","author":"HM DuBrock","year":"2018","unstructured":"DuBrock, H. M., AbouEzzeddine, O. F. & Redfield, M. M. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PLoS ONE 13, e0201836 (2018).","journal-title":"PLoS ONE"},{"key":"5038_CR86","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR87","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR88","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer, C. M. et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: Summit CMR substudy. J. Am. Coll. Cardiol. 85, 699\u2013706 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5038_CR89","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","volume":"12","author":"R Patel","year":"2024","unstructured":"Patel, R. et al. Glp-1 receptor agonists among patients with overweight or obesity, diabetes, and Hfpef on Sglt2 inhibitors. JACC Heart Fail. 12, 1814\u20131826 (2024).","journal-title":"JACC Heart Fail."},{"key":"5038_CR90","doi-asserted-by":"crossref","unstructured":"Stefater-Richards, M. A., Jhe, G. & Zhang, Y. J. Glp-1 receptor agonists in pediatric and adolescent obesity. Pediatrics 155, e2024068119 (2025).","DOI":"10.1542\/peds.2024-068119"},{"key":"5038_CR91","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly, A. S. et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N. Engl. J. Med. 382, 2117\u20132128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR92","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa2407379","volume":"392","author":"CK Fox","year":"2025","unstructured":"Fox, C. K. et al. Liraglutide for children 6 to <12 years of age with obesity - a randomized trial. N. Engl. J. Med. 392, 555\u2013565 (2025).","journal-title":"N. Engl. J. Med."},{"key":"5038_CR93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpeds.2021.05.009","volume":"236","author":"PM Ryan","year":"2021","unstructured":"Ryan, P. M. et al. Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis. J. Pediatr. 236, 137\u2013147.e113 (2021).","journal-title":"J. Pediatr."},{"key":"5038_CR94","doi-asserted-by":"crossref","unstructured":"Kotecha, P. et al. Efficacy and safety of Glp-1 Ras in children and adolescents with obesity or type 2 diabetes: a systematic review and meta-analysis. JAMA Pediatr. 179, 1308\u20131317 (2025).","DOI":"10.1001\/jamapediatrics.2025.3243"},{"key":"5038_CR95","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.jacadv.2024.101411","volume":"3","author":"T Salaets","year":"2024","unstructured":"Salaets, T., Gewillig, M., Van De Bruaene, A. & Mertens, L. L. Right ventricular remodeling and function in hypoplastic left heart syndrome. JACC Adv. 3, 101411 (2024).","journal-title":"JACC Adv."},{"key":"5038_CR96","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.jtcvs.2015.06.076","volume":"150","author":"S Tarui","year":"2015","unstructured":"Tarui, S. et al. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: three-year follow-up of the transcoronary infusion of cardiac progenitor cells in patients with single-ventricle physiology (Ticap) trial. J. Thorac. Cardiovasc Surg. 150, 1198\u20131207 (2015).","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"5038_CR97","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1161\/CIRCRESAHA.116.310253","volume":"120","author":"S Ishigami","year":"2017","unstructured":"Ishigami, S. et al. Intracoronary cardiac progenitor cells in single ventricle physiology: the perseus (cardiac progenitor cell infusion to treat univentricular heart disease) randomized phase 2 trial. Circ. Res. 120, 1162\u20131173 (2017).","journal-title":"Circ. Res."},{"key":"5038_CR98","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","volume":"69","author":"JM Hare","year":"2017","unstructured":"Hare, J. M. et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: Poseidon-DCM Trial. J. Am. Coll. Cardiol. 69, 526\u2013537 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"5038_CR99","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.xjon.2023.09.031","volume":"16","author":"RE Wittenberg","year":"2023","unstructured":"Wittenberg, R. E. et al. Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome. JTCVS Open 16, 656\u2013672 (2023).","journal-title":"JTCVS Open"},{"key":"5038_CR100","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13287-025-04316-3","volume":"16","author":"C Gallego-Navarro","year":"2025","unstructured":"Gallego-Navarro, C. et al. Autologous umbilical cord blood mononuclear cell therapy for hypoplastic left heart syndrome: a nonrandomized control trial of the efficacy and safety of intramyocardial injections. Stem Cell Res. Ther. 16, 215 (2025).","journal-title":"Stem Cell Res. Ther."},{"key":"5038_CR101","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0735-1097(20)31190-6","volume":"75","author":"Y Qureshi Muhammad","year":"2020","unstructured":"Qureshi Muhammad, Y. et al. Autologous stem cell therapy for single right ventricular dysfunction after Fontan operation: phase I safety and feasibility study of intracoronary infusion of bone marrow-derived mononuclear cells. JACC 75, 563\u2013563 (2020).","journal-title":"JACC"},{"key":"5038_CR102","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/sctm.16-0331","volume":"6","author":"M Bervar","year":"2017","unstructured":"Bervar, M. et al. Effects of transendocardial Cd34(+) cell transplantation on diastolic parameters in patients with nonischemic dilated cardiomyopathy. Stem Cells Transl. Med. 6, 1515\u20131521 (2017).","journal-title":"Stem Cells Transl. Med."},{"key":"5038_CR103","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/ejhf.2596","volume":"24","author":"B Vrtovec","year":"2022","unstructured":"Vrtovec, B. et al. A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 24, 1441\u20131449 (2022).","journal-title":"Eur. J. Heart Fail."},{"key":"5038_CR104","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/ehf2.14473","volume":"10","author":"JM Molina-Linde","year":"2023","unstructured":"Molina-Linde, J. M., Cordero-Pereda, D., Banos-Alvarez, E., Rosario-Lozano, M. P. & Blasco-Amaro, J. A. Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review. ESC Heart Fail. 10, 2760\u20132772 (2023).","journal-title":"ESC Heart Fail."},{"key":"5038_CR105","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1002\/ehf2.14940","volume":"11","author":"AC Schafer","year":"2024","unstructured":"Schafer, A. C. et al. Effects of baroreflex activation therapy on cardiac function and morphology. ESC Heart Fail. 11, 3360\u20133367 (2024).","journal-title":"ESC Heart Fail."},{"key":"5038_CR106","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1161\/CIRCHEARTFAILURE.110.955013","volume":"4","author":"HN Sabbah","year":"2011","unstructured":"Sabbah, H. N. et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ. Heart Fail. 4, 65\u201370 (2011).","journal-title":"Circ. Heart Fail."},{"key":"5038_CR107","doi-asserted-by":"publisher","first-page":"H597","DOI":"10.1152\/ajpheart.00329.2022","volume":"323","author":"JS Clemmer","year":"2022","unstructured":"Clemmer, J. S. & Pruett, W. A. Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy. Am. J. Physiol. Heart Circ. Physiol. 323, H597\u2013H607 (2022).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"5038_CR108","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijcard.2023.03.030","volume":"381","author":"HU Kumar","year":"2023","unstructured":"Kumar, H. U. et al. Autonomic regulation therapy in chronic heart failure with preserved\/mildly reduced ejection fraction: Anthem-Hfpef study results. Int. J. Cardiol. 381, 37\u201344 (2023).","journal-title":"Int. J. Cardiol."},{"key":"5038_CR109","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.brs.2014.07.031","volume":"7","author":"JA Clancy","year":"2014","unstructured":"Clancy, J. A. et al. Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. Brain Stimul. 7, 871\u2013877 (2014).","journal-title":"Brain Stimul."},{"key":"5038_CR110","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.brs.2017.05.006","volume":"10","author":"D Antonino","year":"2017","unstructured":"Antonino, D. et al. Non-Invasive vagus nerve stimulation acutely improves spontaneous cardiac baroreflex sensitivity in healthy young men: a randomized placebo-controlled trial. Brain Stimul. 10, 875\u2013881 (2017).","journal-title":"Brain Stimul."},{"key":"5038_CR111","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/eurheartj\/ehaf037","volume":"46","author":"GL Ackland","year":"2025","unstructured":"Ackland, G. L. et al. Non-invasive vagus nerve stimulation and exercise capacity in healthy volunteers: a randomized trial. Eur. Heart J. 46, 1634\u20131644 (2025).","journal-title":"Eur. Heart J."},{"key":"5038_CR112","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1113\/EP087351","volume":"104","author":"L Zhou","year":"2019","unstructured":"Zhou, L. et al. Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction. Exp. Physiol. 104, 28\u201338 (2019).","journal-title":"Exp. Physiol."},{"key":"5038_CR113","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009288","volume":"15","author":"K Elkholey","year":"2022","unstructured":"Elkholey, K. et al. Transcutaneous vagus nerve stimulation ameliorates the phenotype of heart failure with preserved ejection fraction through its anti-inflammatory effects. Circ. Heart Fail. 15, e009288 (2022).","journal-title":"Circ. Heart Fail."},{"key":"5038_CR114","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12265-018-9853-6","volume":"12","author":"N Tran","year":"2019","unstructured":"Tran, N. et al. Autonomic neuromodulation acutely ameliorates left ventricular strain in humans. J. Cardiovasc. Transl. Res. 12, 221\u2013230 (2019).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"5038_CR115","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023582","volume":"11","author":"S Stavrakis","year":"2022","unstructured":"Stavrakis, S. et al. Neuromodulation of inflammation to treat heart failure with preserved ejection fraction: a pilot randomized clinical trial. J. Am. Heart Assoc. 11, e023582 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"5038_CR116","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/epi.12762","volume":"55","author":"I Orosz","year":"2014","unstructured":"Orosz, I. et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia 55, 1576\u20131584 (2014).","journal-title":"Epilepsia"},{"key":"5038_CR117","doi-asserted-by":"publisher","first-page":"1190062","DOI":"10.3389\/fneur.2023.1190062","volume":"14","author":"D Song","year":"2023","unstructured":"Song, D., Li, P., Wang, Y. & Cao, J. Noninvasive vagus nerve stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials. Front. Neurol. 14, 1190062 (2023).","journal-title":"Front. Neurol."},{"key":"5038_CR118","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","volume":"7","author":"BA Borlaug","year":"2019","unstructured":"Borlaug, B. A. & Reddy, Y. N. V. The role of the pericardium in heart failure: implications for pathophysiology and treatment. JACC Heart Fail. 7, 574\u2013585 (2019).","journal-title":"JACC Heart Fail."},{"key":"5038_CR119","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V. & Borlaug, B. A. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136, 6\u201319 (2017).","journal-title":"Circulation"},{"key":"5038_CR120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003612","volume":"10","author":"BA Borlaug","year":"2017","unstructured":"Borlaug, B. A. et al. Percutaneous pericardial resection: a novel potential treatment for heart failure with preserved ejection fraction. Circ. Heart Fail 10, e003612 (2017).","journal-title":"Circ. Heart Fail"},{"key":"5038_CR121","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1093\/eurheartj\/ehad620","volume":"44","author":"BA Borlaug","year":"2023","unstructured":"Borlaug, B. A. et al. Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study. Eur. Heart J. 44, 4719\u20134721 (2023).","journal-title":"Eur. Heart J."},{"key":"5038_CR122","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jacbts.2024.02.010","volume":"9","author":"BA Borlaug","year":"2024","unstructured":"Borlaug, B. A. & Strong, M. Heart failure solutions: the pericut device as a treatment for Hfpef. JACC Basic Transl. Sci. 9, 448\u2013450 (2024).","journal-title":"JACC Basic Transl. Sci."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05038-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05038-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05038-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:03:24Z","timestamp":1779289404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05038-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":122,"alternative-id":["5038"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05038-9","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}